BioPharmX

BioPharmX today announced positive results from its Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea. BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator’s Global Assessment (IGA) scale from baseline to week 12. https://bit.ly/2XrDXYX

Approximately 40 to 50 million Americans suffer from acne vulgaris. We are developing BPX-01, a topical version of minocycline, for these patients. Learn more:

BioPharmX Reports Fiscal First Quarter 2020 Financial Results https://bit.ly/2KdWd1t

Acne is the most common skin condition that people experience. Most people develop acne to some degree during their lifetime. Understand the underlying causes of acne:

In a Phase 2b study, BPX-01 demonstrated a 58% reduction in inflammatory acne lesions. Learn about our development of a novel, proprietary topical minocycline gel for acne vulgaris:

BPX-04 was designed to deliver minocycline topically for rosacea patients looking to minimize systemic exposure to antibiotics. Learn more about the development program here:

Rosacea is a common skin disease that can cause redness, swelling, and acne-like breakouts. The American Academy of Dermatology provides an overview:

Our HyantX delivery system was designed to minimize the dosage required of a drug through enhanced targeted delivery, thereby limiting skin irritation associated with excess drug on the skin. Learn more from our CEO's latest presentation:

BioPharmX is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. Visit our website to learn more:

BioPharmX announced today that the last patient in the Company’s Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea, has completed their last clinical visit. Details here: https://bit.ly/2QilAPX

Reverse stock split is complete.

BioPharmX Announces Reverse Stock Split.

BioPharmX Announces $3.9 Million Offering.

BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results.